XALKORI ROS1+NSCLC DRUG USE INVESTIGATION
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• patients with unresectable progressive/recurrent NSCLC who are naive to XALKORI and whose tumor is ROS1 gene positive
Locations
Other Locations
Japan
Pfizer Tokyo
RECRUITING
Tokyo
Contact Information
Primary
Pfizer CT.gov Call Center
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Time Frame
Start Date: 2017-10-25
Estimated Completion Date: 2027-03-26
Participants
Target number of participants: 100
Treatments
crizotinib
Related Therapeutic Areas
Sponsors
Leads: Pfizer